Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma

Adenoid cystic carcinoma (ACC) is a rare type of malignant tracheal tumor originating from the secretory glands. Complete surgical resection is the current standard of care for tracheal ACC. However, there have been few case reports of chemoradiotherapy for unresectable tracheal ACC. We herein repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikami, Erika, Nakamichi, Shinji, Nagano, Atsuhiro, Misawa, Kazuhito, Hayashi, Anna, Tozuka, Takehiro, Takano, Natsuki, Noro, Rintaro, Maebayashi, Katsuya, Kubokura, Hirotoshi, Terasaki, Yasuhiro, Kubota, Kaoru, Seike, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569923/
https://www.ncbi.nlm.nih.gov/pubmed/36642523
http://dx.doi.org/10.2169/internalmedicine.1142-22
Descripción
Sumario:Adenoid cystic carcinoma (ACC) is a rare type of malignant tracheal tumor originating from the secretory glands. Complete surgical resection is the current standard of care for tracheal ACC. However, there have been few case reports of chemoradiotherapy for unresectable tracheal ACC. We herein report a 28-year-old man with unresectable tracheal ACC who received concurrent chemoradiotherapy (CCRT) followed by maintenance therapy with durvalumab. CCRT was completed with a good response and safety, and the patient is currently receiving durvalumab as maintenance therapy. Durvalumab after CCRT can be a treatment option for patients with unresectable tracheal ACC.

Ejemplares similares